Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and Pi3K/AKT/mTOR pathways

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 1, 2014, Pages 203-215

  Hosford, Sarah R ^a   Miller, Todd W ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Mammalian target of rapamycin; Palbociclib; Phosphoinositide3 kinase

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTIESTROGEN; APITOLISIB; BUPARLISIB; BYL 719; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; EVEROLIMUS; EXEMESTANE; FULVESTRANT; HISTONE DEACETYLASE; JANUS KINASE; LEE 011; LETROZOLE; LY 2835219; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT PROTEIN; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST METASTASIS; CANCER INHIBITION; CELL CYCLE PHASE; CELL CYCLE REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; MITOSIS INHIBITION; MOLECULAR MECHANICS; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER;

EID: 84905663688     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S52762     Document Type: Review

References (156)

1. American Cancer Society. Breast Cancer: Facts and Figures 2013-2014. Atlanta, GA: American Cancer Society, Inc.; 2013.
2. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403): 346-352.
3. Sørlie T, Perou CM, Tibshirani R, etal. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19): 10869-10874.
4. Prat A, Parker JS, Karginova O, etal. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12(5): R68.
5. Perou CM, Sørlie T, Eisen MB, etal. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747-752.
6. Bertucci F, Finetti P, Cervera N, etal. How basal are triple-negative breast cancers? Int J Cancer. 2008; 123(1): 236-240.
7. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012; 17(1): 1-16.
8. Giuliano M, Schifp R, Osborne CK, Trivedi MV. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011; 20: Suppl 3: 42-49.
9. Anders L, Ke N, Hydbring P, etal. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011; 20(5): 620-634.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-674.
11. Fleming TP, Matsui T, Molloy CJ, Robbins KC, Aaronson SA. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc Natl Acad Sci U S A. 1989; 86(20): 8063-8067.
12. Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat. 1995; 35(1): 133-144.
13. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011; 11(8): 558-572.
14. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001; 1(3): 222-231.
15. Bignell GR, Greenman CD, Davies H, etal. Signatures of mutation and selection in the cancer genome. Nature. 2010; 463(7283): 893-898.
16. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70.
17. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996; 68: 67-108.
18. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 2009; 16(2): 36-43.
19. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle. 2004; 3(12): 1537-1542.
20. Byrd JC, Shinn C, Waselenko JK, etal. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998; 92(10): 3804-3816.
21. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000; 96(2): 393-397.
22. Shapiro GI, Supko JG, Patterson A, etal. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res. 2001; 7(6): 1590-1599.
23. Schwartz GK, Ilson D, Saltz L, etal. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol. 2001; 19(7): 1985-1992.
24. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol. 2003; 14(8): 1270-1273.
25. Liu G, Gandara DR, Lara PN, etal. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004; 10(3): 924-928.
26. Canavese M, Santo L, Raje N. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther. 2012; 13(7): 451-457.
27. Toogood PL, Harvey PJ, Repine JT, etal. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 2005; 48(7): 2388-2406.
28. Fry DW, Harvey PJ, Keller PR, etal. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004; 3(11): 1427-1438.
29. Finn RS, Dering J, Conklin D, etal. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009; 11(5): R77.
30. Miller TW, Balko JM, Fox EM, etal. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011; 1(4): 338-351.
31. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev. 2001; 53(1): 25-71.
32. Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol. 1995; 9(12): 1804-1813.
33. Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1994; 31(1): 95-105.
34. Carroll JS, Prall OW, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem. 2000; 275(49): 38221-38229.
35. Wilcken NR, Prall OW, Musgrove EA, Sutherland RL. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res. 1997; 3(6): 849-854.
36. Rudas M, Lehnert M, Huynh A, etal; Austrian Breast and Colorectal Cancer Study Group. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res. 2008; 14(6): 1767-1774.
37. Bosco EE, Wang Y, Xu H, etal. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest. 2007; 117(1): 218-228.
38. Thangavel C, Dean JL, Ertel A, etal. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011; 18(3): 333-345.
39. Kim S, Loo A, Chopra R, etal. Abstract PR02: LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6-reactivating Rb in cancer. Mol Cancer Ther. 2013; 12: PR02.
40. Schwartz GK, LoRusso PM, Dickson MA, etal. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011; 104(12): 1862-1868.
41. Flaherty KT, Lorusso PM, Demichele A, etal. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012; 18(2): 568-576.
42. Finn RS, Crown JP, Boer K, etal. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer(BC). 2012 Cancer Res. 2012; 72(Suppl 24): S1-S6.
43. Infante JR, Petronella W, Gerecitano J, et al. A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol. 2014; 32(5s Suppl): Abstract 2528.
44. Shapiro G, Lee S, Tolcher AW, etal. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol. 2013; 31Suppl: Abstract 2500.
45. McClendon AK, Dean JL, Rivadeneira DB, etal. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012; 11(14): 2747-2755.
46. Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem. 2012; 287(34): 29075-29087.
47. Roberts PJ, Bisi JE, Strum JC, etal. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012; 104(6): 476-487.
48. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7): 489-501.
49. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001; 17: 615-675.
50. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004; 9(6): 667-676.
51. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011; 13(6): 224.
52. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013; 71(4): 829-842.
53. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011; 29(33): 4452-4461.
54. Razis E, Bobos M, Kotoula V, etal. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011; 128(2): 447-456.
55. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol. 2005; 18(2): 250-259.
56. Saal LH, Johansson P, Holm K, etal. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007; 104(18): 7564-7569.
57. Pérez-Tenorio G, Alkhori L, Olsson B, etal. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007; 13(12): 3577-3584.
58. Gonzalez-Angulo Am, Ferrer-Lozano J, Stemke-Hale K, etal. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011; 10(6): 1093-1101.
59. Bendell JC, Rodon J, Burris HA, etal. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012; 30(3): 282-290.
60. Doi T, Ando Y, Bando H, etal. Phase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Mol Cancer Ther. 2011; 10(11 Supplement 1): Abstract B159.
61. Rodon J, Bendell JC, Abdul RAR, etal. Safety profile and clinical activity of single-agent BKM120, a pan-class I PIK inhibitor, for the treatment of patients with metastatic breast carcinoma. Cancer Res. 2011; 71(24 Suppl 3): Abstract P3-16-01.
62. Gonzalez-Angulo AM, Juric D, Argilés G, etal. Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: results from the first-in-human study. J Clin Oncol. 2013; 31 Suppl: Abstract 2531.
63. Miller TW, Hennessy BT, González-Angulo AM, etal. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010; 120(7): 2406-2413.
64. O'Brien C, Wallin JJ, Sampath D, etal. Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010; 16(14): 3670-3683.
65. She QB, Chandarlapaty S, Ye Q, etal. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One. 2008; 3(8): e3065.
66. Ihle NT, Lemos R Jr, Wipf P, etal. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009; 69(1): 143-150.
67. Wallin JJ, Edgar KA, Guan J, etal. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011; 10(12): 2426-2436.
68. Mayer IA, Balko JM, Kuba MG, etal. SU2C phase Ib study of pan-PI3K inhibitor BKM120 plus aromatase inhibitor letrozole in ER+/HER2-metastatic breast cancer (MBC). Cancer Res. 2011; 71(24 Suppl 3): Abstract PD09-05.
69. Janku F, Wheler JJ, Westin SN, etal. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30(8): 777-782.
70. Maass N, Harbeck N, Mundhenke C, etal; German Breast Group. Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. J Cancer Res Clin Oncol. 2013; 139(12): 2047-2056.
71. Cavazzoni A, Bonelli MA, Fumarola C, etal. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Lett. 2012; 323(1): 77-87.
72. Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov. 2010; 5(1): 29-57.
73. Ghayad SE, Bieche I, Vendrell JA, etal. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008; 99(10): 1992-2003.
74. Vilquin P, Villedieu M, Grisard E, etal. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer. 2013; 133(7): 1589-1602.
75. Bachelot T, Bourgier C, Cropet C, etal. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012; 30(22): 2718-2724.
76. Yardley DA, Noguchi S, Pritchard KI, etal. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013; 30(10): 870-884.
77. Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, etal. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol. 2013; 31 Suppl: Abstract LBA509.
78. Miller TW, Forbes JT, Shah C, etal. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res. 2009; 15(23): 7266-7276.
79. O'Reilly KE, Rojo F, She QB, etal. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66(3): 1500-1508.
80. Carracedo A, Ma L, Teruya-Feldstein J, etal. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118(9): 3065-3074.
81. Mayer IA, Abramson VG, Balko JM, etal. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2-metastatic breast cancer (MBC). J Clin Oncol. 2012; 30 Suppl: Abstract 510.
82. Perez EA, Dueck AC, McCullough AE, etal. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol. 2013; 31(17): 2115-2122.
83. Berns K, Horlings HM, Hennessy BT, etal. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4): 395-402.
84. O'Brien NA, Browne BC, Chow L, etal. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 2010; 9(6): 1489-1502.
85. Wang L, Zhang Q, Zhang J, etal. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer. 2011; 11: 248.
86. Esteva FJ, Guo H, Zhang S, etal. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010; 177(4): 1647-1656.
87. O'Brien NA, McDonald K, Tong L, etal. PI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKT. Cancer Res. 2012; 72(24 Suppl 3): Abstract P4-08-01.
88. Saura C, Bendell J, Jerusalem G, etal. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014; 20(7): 1935-1945.
89. Morrow PK, Wulf GM, Ensor J, etal. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011; 29(23): 3126-3132.
90. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002; 5(6): 234-248.
91. Massarweh S, Osborne CK, Creighton CJ, etal. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008; 68(3): 826-833.
92. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001; 93(24): 1852-1857.
93. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology. 1999; 57(4): 330-340.
94. Creighton CJ, Casa A, Lazard Z, etal. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008; 26(25): 4078-4085.
95. Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 1990; 50(21): 6931-6935.
96. Fox EM, Miller TW, Balko JM, etal. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011; 71(21): 6773-6784.
97. Quek R, Wang Q, Morgan JA, etal. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011; 17(4): 871-879.
98. Cao AZ, Pinzon-Ortiz M, Chen Y, etal. Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab. J Clin Oncol. 2013; 31 Suppl: Abstract e13525.
99. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(4): 423-429.
100. Cohen BD, Baker DA, Soderstrom C, etal. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res. 2005; 11(5): 2063-2073.
101. Robertson JF, Ferrero JM, Bourgeois H, etal. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013; 14(3): 228-235.
102. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997; 57(13): 2687-2693.
103. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat. 1999; 56(1): 1-10.
104. Haluska P, Shaw H, Batzel GN, etal. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751, 871 in patients with refractory solid tumors. J Clin Oncol. 2007; 25(Suppl 18): Abstract 3586.
105. Karp DD, Paz-Ares LG, Novello S, etal. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751, 871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 2009; 27(15): 2516-2522.
106. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23): 11118-11128.
107. Friedbichler K, Hofmann MH, Kroez M, et al. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther. 2014; 13(2): 399-409.
108. Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010; 12(6): 215.
109. Hershman DL, McMahon DJ, Crew KD, etal. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008; 26(29): 4739-4745.
110. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, etal; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9(9): 840-849.
111. Shapiro CL, Halabi S, Hars V, etal. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011; 47(5): 683-689.
112. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004; 9 Suppl 4: 3-13.
113. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008; 34(5): 453-475.
114. Daubiné F, Le Gall C, Gasser J, Green J, Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007; 99(4): 322-330.
115. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2010; 126(2): 522-532.
116. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004; 10(13): 4559-4567.
117. Gnant M. Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict? Curr Oncol Rep. 2012; 14(1): 35-43.
118. Dent R, Trudeau M, Pritchard KI, etal. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1): 4429-4434.
119. Kennecke H, Yerushalmi R, Woods R, etal. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28(20): 3271-3277.
120. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006; 12(9): 440-450.
121. McCabe N, Turner NC, Lord CJ, etal. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16): 8109-8115.
122. Bryant HE, Schultz N, Thomas HD, etal. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035): 913-917.
123. Farmer H, McCabe N, Lord CJ, etal. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035): 917-921.
124. Murai J, Huang SY, Das BB, etal. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012; 72(21): 5588-5599.
125. Murai J, Huang SY, Renaud A, etal. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014; 13(2): 433-443.
126. Tutt A, Robson M, Garber JE, etal. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737): 235-244.
127. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004; 4(10): 814-819.
128. Dent RA, Lindeman GJ, Clemons M, etal. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013; 15(5): R88.
129. Kristeleit RS, Shapiro G, LoRusso P, etal. A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors. J Clin Oncol. 2013; 31 Suppl: Abstract 2585.
130. Isakoff SJ, Overmoyer B, Tung NM, etal. A phase II trial expansion cohort of the PARP inhibitor veliparib (ABT888) and temozolomide in BRCA1/2 associated metastatic breast cancer. Cancer Res. 2011; 71(24 Suppl 3): P3-16-05.
131. Fan J, Yin WJ, Lu JS, etal. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008; 134(8): 883-890.
132. Jang ER, Lim SJ, Lee ES, etal. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene. 2004; 23(9): 1724-1736.
133. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011; 130(2): 437-447.
134. Yardley DA, Ismail-Khan RR, Melichar B, etal. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013; 31(17): 2128-2135.
135. Munster PN, Thurn KT, Thomas S, etal. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011; 104(12): 1828-1835.
136. Conte P, Campone M, Pronzato P, etal. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety and tolerability results. J Clin Oncol. 2009; 27(15s Suppl): Abstract 1081.
137. Frame MC. Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta. 2002; 1602(2): 114-130.
138. Zhang XH, Wang Q, Gerald W, etal. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009; 16(1): 67-78.
139. Elsberger B, Tan BA, Mitchell TJ, etal. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR-and HER2-negative breast cancer patients? Am J Pathol. 2009; 175(4): 1389-1397.
140. Elsberger B, Tan BA, Mallon EA, Brunton VG, Edwards J. Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival. Br J Cancer. 2010; 103(12): 1831-1834.
141. Morgan L, Gee J, Pumford S, etal. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther. 2009; 8(16): 1550-1558.
142. Herold CI, Chadaram V, Peterson BL, etal. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res. 2011; 17(18): 6061-6070.
143. Finn RS, Bengala C, Ibrahim N, etal. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res. 2011; 17(21): 6905-6913.
144. Fedele P, Calvani N, Marino A, etal. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol. 2012; 84(2): 243-251.
145. Fornier MN, Morris PG, Abbruzzi A, etal. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol. 2011; 22(12): 2575-2581.
146. Somlo G, Atzori F, Strauss LC, etal. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res. 2013; 19(7): 1884-1893.
147. Paul D, Vukelja SJ, Holmes FA, etal. Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy. Cancer Res. 2013; 73: Abstract S3-07.
148. Bristol-Myers Squibb. Safety and efficacy of exemestane plus dasatinib versus placebo for advanced ER+ breast cancer. Available from: http: //clinicaltrials.gov/show/NCT00767520. NLM identifier: NCT00767520. Accessed March 14, 2014.
149. Parganas E, Wang D, Stravopodis D, etal. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998; 93(3): 385-395.
150. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007; 7(9): 673-683.
151. Levine RL, Wadleigh M, Cools J, etal. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4): 387-397.
152. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012; 30(9): 1005-1014.
153. Marotta LL, Almendro V, Marusyk A, etal. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24-stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011; 121(7): 2723-2735.
154. Britschgi A, Andraos R, Brinkhaus H, etal. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012; 22(6): 796-811.
155. Cerami E, Gao J, Dogrusoz U, etal. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5): 401-404.
156. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269): p 11.